LES Announces Results of 2024 Life Sciences Royalty Rates & Deal Terms Survey

Wakefield, MA  – June 18, 2025 – The Licensing Executives Society (USA & Canada), Inc. (LES) is announcing the release of the 2024 Life Sciences Royalty Rates & Deal Terms Survey Results, a comprehensive benchmarking resource for professionals involved in licensing, dealmaking, and valuation in the life sciences sector. The survey provides current data on royalty rates, upfront payments, milestone terms, and other key deal components across biopharmaceuticals, medical devices, diagnostics, and related fields. The report captures trends and real-world deal terms that help industry professionals benchmark agreements and inform negotiations.

The 2024 survey results are compiled from data submitted by licensing professionals, legal counsel, business development executives, and others involved in life sciences dealmaking. This wide range of contributors ensures the survey reflects diverse deal structures and terms across various subsectors and geographies. The report provides insights into how licensing terms have evolved, enabling users to compare their deals against current market standards and make more informed strategic decisions.

2024 Survey Highlights:

  • 149 total responses were considered complete for analysis and incorporated into this report. 
  • Survey respondents represented 7 of the 31 Licensing Executive Society International (LESI) Societies. 
  • Respondents based on number of Deals used in the analysis: 44% Not-for-Profit, 27% Operating Companies, Organizations, 3% Government, and 27% Other.  Of the Operating companies, 68% were Biotech and 20% were Pharmaceutical.  For Not-for-Profit Organizations, 72% were academic and 23% were hospitals.
  • Respondent by Organization Composition: 23% Pharmaceutical Companies (includes Diagnostic and Drug Delivery), 73% Biotech Companies (includes Device), 5% Other.

The full survey results report is available for purchase for $795, but members of the Licensing Executives Society, USA & Canada, receive complimentary access to all of our industry surveys as a key membership benefit. Many professionals join LES to gain access to this report and other exclusive licensing resources.

For more information on purchasing the 2024 Life Sciences Royalty Rates & Deal Terms Survey Results or on becoming an LES member to receive the report for free, please visit lesusacanada.org.


About Licensing Executives Society, USA & Canada:

LES (USA & Canada) is a leading association serving professionals who manage, develop, and commercialize intellectual property. LES provides education, networking, and benchmarking tools to support licensing and intellectual asset management.

LES has been instrumental in establishing standards, industry best practices, education to advance the professional acumen of licensing and IP professionals and is instrumental in bringing together diverse industries and leaders to help advance innovation.

 

For more information, contact:

communications@les.org

 

###

Share this article: